Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.33 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.33 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.33 |
| ▸ | HRH1 known ✓ | P35367 | 1/20 | 0.33 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.33 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.35 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.33 |
| ▸ | EPOR | P19235 | 1/20 | 0.33 |
| ▸ | PGR | P06401 | 1/20 | 0.33 |
| ▸ | FDPS | P14324 | 1/20 | 0.33 |
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.32 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11269612 | 0.98 | TDP1 (0.40) | TDP1SMN1; SMN2SLC22A6FFAR3EPOR | |
| SCHEMBL1172848 | 0.98 | TDP1 (0.40) | TDP1SMN1; SMN2SLC22A6FFAR3EPOR | |
| SCHEMBL17091640 | 0.84 | ALDH1A1 (0.38) | TDP1SMN1; SMN2FFAR3FOLH1ALDH1A1 | |
| SCHEMBL14558025 | 0.84 | TDP1 (0.33) | TDP1SMN1; SMN2SLC22A6EPORPGR | |
| SCHEMBL2672330 | 0.82 | SLC22A6 (0.35) | TDP1SMN1; SMN2SLC22A6FFAR3PGR | |
| SCHEMBL28466576 | 0.80 | FDPS (0.39) | TDP1SMN1; SMN2SLC22A6FFAR3EPOR | |
| SCHEMBL6431287 | 0.80 | FDPS (0.39) | TDP1SMN1; SMN2SLC22A6FFAR3EPOR | |
| SCHEMBL755816 | 0.80 | HTR2A (0.32) | TDP1PGRADRA2AADRA2BHTR2A | |
| SCHEMBL18526737 | 0.80 | HTR2A (0.32) | TDP1PGRADRA2AADRA2BHTR2A | |
| Hydrochloric Acid SCHEMBL3981096 | 0.79 | TET2 (0.45) | PGRADRA2AADRA2BHTR2AHRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117510500-A | Preparation method of asperazepanones alkaloid and application of asperazepanones alkaloid as anti-inflammatory drug | 中国海洋大学 | 2024-02-06 | — | — | CN | claimed |
| US-20260091082-A1 | CYCLIC PEPTIDE DERIVATIVE COMPOSITION FOR TREATING OR PREVENTING EYE DISEASE | DKS CO. LTD. (JP) | 2026-04-02 | — | — | US | disclosed |
| US-20260035407-A1 | CYCLIC PEPTIDE DERIVATIVE, METHOD FOR PRODUCING SAME, AND COMPOSITION | DKS CO. LTD. (JP) | 2026-02-05 | — | — | US | disclosed |
| EP-4613283-A1 | CYCLIC PEPTIDE DERIVATIVE COMPOSITION FOR TREATING OR PREVENTING NEUROPATHIC PAIN AND/OR INFLAMMATORY PAIN | DKS Co. Ltd. (JP) | 2025-09-10 | — | — | EP | disclosed |
| EP-4613282-A1 | CYCLIC PEPTIDE DERIVATIVE COMPOSITION FOR TREATING OR PREVENTING CENTRAL NERVOUS SYSTEM INJURY/DISEASE | DKS Co. Ltd. (JP) | 2025-09-10 | — | — | EP | disclosed |
| EP-4595973-A1 | CYCLIC PEPTIDE DERIVATIVE COMPOSITION FOR TREATING OR PREVENTING EYE DISEASE | DKS Co. Ltd. (JP) | 2025-08-06 | — | — | EP | disclosed |
| EP-4567042-A1 | CYCLIC PEPTIDE DERIVATIVE, METHOD FOR PRODUCING SAME, AND COMPOSITION | DKS Co. Ltd. (JP) | 2025-06-11 | — | — | EP | disclosed |
| CN-115090422-B | Amino acid type collector, and preparation method and application thereof | 山东理工大学 | 2024-04-26 | — | — | CN | disclosed |
| CN-113999136-B | Rhein derivative, preparation method and application thereof, and liver cancer inhibitor specifically expressed by RECQL4 | 山东第一医科大学(山东省医学科学院) | 2023-08-04 | — | — | CN | disclosed |
| US-20230174497-A1 | RHEIN AMIDE DERIVATIVE AND PREPARATION METHOD AND USE THEREOF, AND INHIBITOR OF HEPATOCELLULAR CARCINOMA (HCC) WITH SPECIFIC RECQL4 EXPRESSION | Shandong First Medical University & Shandong Academy Of Medical Sciences (CN) | 2023-06-08 | — | — | US | disclosed |
| US-7754684-B2 | Macromolecular platinum chelates | ACCESS PHARMACEUTICALS, INC. (US) | 2010-07-13 | — | — | US | disclosed |
| US-20050038109-A1 | Macromolecular platinum chelates | ACCESS PHARMACEUTICALS, INC. | 2005-02-17 | — | — | US | disclosed |
| WO-2005002508-A2 | MACROMOLECULAR PLATINUM CHELATES | ACCESS PHARMACEUTICALS, INC. (US) | 2005-01-13 | — | — | WO | disclosed |
| US-6472533-B1 | SUCH AS PHOSPHINE OXAZOLINES; HIGH ENANTIOSELECTIVITY; CATALYSTS FOR SYNTHESIS OF ACTIVE MATERIALS FOR PHARMACEU-TICALS, AGROCHEMICALS, FRAGRANCES AND FOOD ADDITIVES; EFFICIENT | THE TEXAS A & M UNIVERSITY SYSTEM | 2002-10-29 | — | — | US | disclosed |
| EP-1165574-A1 | NOVEL LIGANDS FOR CHIRAL CATALYSIS | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2002-01-02 | — | — | EP | disclosed |
| WO-2000061589-A1 | NOVEL LIGANDS FOR CHIRAL CATALYSIS | THE TEXAS A & M UNIVERSITY SYSTEM (US) | 2000-10-19 | — | — | WO | disclosed |
| EP-0204440-B1 | AZETIDINE DERIVATIVES PRODUCTION | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1990-12-12 | — | — | EP | disclosed |
| EP-0204440-A1 | Azetidine derivatives production | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1986-12-10 | — | — | EP | disclosed |
| US-4518587-A | NERVOUS SYSTEM DISORDERS | S.A. PANMEDICA (FR) | 1985-05-21 | — | — | US | disclosed |
| US-4328367-A | HERBICIDE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1982-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260091082-A1 | CYCLIC PEPTIDE DERIVATIVE COMPOSITION FOR TREATING OR PREVENTING EYE DISEASE | ADCY3, GLP1R, PDE6C | ADRA2A 2302/4885ADRA2B 1721/4885HTR2A 2826/4885 |
| US-20050038109-A1 | Macromolecular platinum chelates | FOLR1, LIG3, ABCC1 | ADRA2A 4789/4885ADRA2B 4785/4885HTR2A 4540/4885 |
| US-20260035407-A1 | CYCLIC PEPTIDE DERIVATIVE, METHOD FOR PRODUCING SAME, AND COMPOSITION | BDNF, VIP, CA3 | ADRA2A 2894/4885ADRA2B 2768/4885HTR2A 1863/4885 |
| US-20230174497-A1 | RHEIN AMIDE DERIVATIVE AND PREPARATION METHOD AND USE THEREOF, AND INHIBITOR OF HEPATOCELLULAR CARCINOMA (HCC) WITH SPECIFIC RECQL4 EXPRESSION | RECQL, MRTO4, SNU13 | ADRA2A 4106/4885ADRA2B 4270/4885HTR2A 4454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.